EA008927B1 - Применение производных 2h-[1,3]оксазино[3,2-a]индола для лечения невропатической боли - Google Patents
Применение производных 2h-[1,3]оксазино[3,2-a]индола для лечения невропатической боли Download PDFInfo
- Publication number
- EA008927B1 EA008927B1 EA200600270A EA200600270A EA008927B1 EA 008927 B1 EA008927 B1 EA 008927B1 EA 200600270 A EA200600270 A EA 200600270A EA 200600270 A EA200600270 A EA 200600270A EA 008927 B1 EA008927 B1 EA 008927B1
- Authority
- EA
- Eurasian Patent Office
- Prior art keywords
- neuropathic pain
- treatment
- compound
- pain
- formula
- Prior art date
Links
- 208000004296 neuralgia Diseases 0.000 title claims abstract description 18
- 208000021722 neuropathic pain Diseases 0.000 title claims abstract description 16
- KGVOXAQTJVXNNV-UHFFFAOYSA-N 2h-[1,3]oxazino[3,2-a]indole Chemical class C1=CC=C2N(C=CCO3)C3=CC2=C1 KGVOXAQTJVXNNV-UHFFFAOYSA-N 0.000 title 1
- 150000001875 compounds Chemical class 0.000 claims abstract description 25
- 239000008194 pharmaceutical composition Substances 0.000 claims abstract description 10
- 239000002253 acid Substances 0.000 claims abstract description 7
- 150000007522 mineralic acids Chemical class 0.000 claims abstract description 7
- 150000007524 organic acids Chemical class 0.000 claims abstract description 7
- 150000003839 salts Chemical class 0.000 claims abstract description 7
- 125000000217 alkyl group Chemical group 0.000 claims abstract description 6
- 125000004432 carbon atom Chemical group C* 0.000 claims abstract description 6
- 125000003710 aryl alkyl group Chemical group 0.000 claims abstract description 5
- 125000004210 cyclohexylmethyl group Chemical group [H]C([H])(*)C1([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C1([H])[H] 0.000 claims description 3
- 125000004108 n-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 claims description 3
- 125000003118 aryl group Chemical group 0.000 claims description 2
- 125000001624 naphthyl group Chemical group 0.000 claims description 2
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims description 2
- 238000002360 preparation method Methods 0.000 claims description 2
- 239000012634 fragment Substances 0.000 claims 1
- 241000700159 Rattus Species 0.000 description 12
- 208000004454 Hyperalgesia Diseases 0.000 description 11
- 241001465754 Metazoa Species 0.000 description 8
- 208000002193 Pain Diseases 0.000 description 7
- 239000002552 dosage form Substances 0.000 description 7
- 210000003497 sciatic nerve Anatomy 0.000 description 7
- 206010053552 allodynia Diseases 0.000 description 6
- 208000000094 Chronic Pain Diseases 0.000 description 5
- ZSJLQEPLLKMAKR-GKHCUFPYSA-N streptozocin Chemical compound O=NN(C)C(=O)N[C@H]1[C@@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O ZSJLQEPLLKMAKR-GKHCUFPYSA-N 0.000 description 5
- 229960001052 streptozocin Drugs 0.000 description 5
- 208000011580 syndromic disease Diseases 0.000 description 5
- 238000012360 testing method Methods 0.000 description 5
- 208000000114 Pain Threshold Diseases 0.000 description 4
- ZSJLQEPLLKMAKR-UHFFFAOYSA-N Streptozotocin Natural products O=NN(C)C(=O)NC1C(O)OC(CO)C(O)C1O ZSJLQEPLLKMAKR-UHFFFAOYSA-N 0.000 description 4
- 206010012601 diabetes mellitus Diseases 0.000 description 4
- 239000007924 injection Substances 0.000 description 4
- 238000002347 injection Methods 0.000 description 4
- 230000037040 pain threshold Effects 0.000 description 4
- 239000000243 solution Substances 0.000 description 4
- 241000282412 Homo Species 0.000 description 3
- 208000035154 Hyperesthesia Diseases 0.000 description 3
- 238000006243 chemical reaction Methods 0.000 description 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 3
- 229940079593 drug Drugs 0.000 description 3
- 239000003814 drug Substances 0.000 description 3
- 210000000548 hind-foot Anatomy 0.000 description 3
- 238000000034 method Methods 0.000 description 3
- 239000000203 mixture Substances 0.000 description 3
- 230000001575 pathological effect Effects 0.000 description 3
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 3
- QCQCHGYLTSGIGX-GHXANHINSA-N 4-[[(3ar,5ar,5br,7ar,9s,11ar,11br,13as)-5a,5b,8,8,11a-pentamethyl-3a-[(5-methylpyridine-3-carbonyl)amino]-2-oxo-1-propan-2-yl-4,5,6,7,7a,9,10,11,11b,12,13,13a-dodecahydro-3h-cyclopenta[a]chrysen-9-yl]oxy]-2,2-dimethyl-4-oxobutanoic acid Chemical compound N([C@@]12CC[C@@]3(C)[C@]4(C)CC[C@H]5C(C)(C)[C@@H](OC(=O)CC(C)(C)C(O)=O)CC[C@]5(C)[C@H]4CC[C@@H]3C1=C(C(C2)=O)C(C)C)C(=O)C1=CN=CC(C)=C1 QCQCHGYLTSGIGX-GHXANHINSA-N 0.000 description 2
- 208000032131 Diabetic Neuropathies Diseases 0.000 description 2
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 2
- 206010061598 Immunodeficiency Diseases 0.000 description 2
- 208000029462 Immunodeficiency disease Diseases 0.000 description 2
- 206010028980 Neoplasm Diseases 0.000 description 2
- 230000000202 analgesic effect Effects 0.000 description 2
- 201000011510 cancer Diseases 0.000 description 2
- 201000010099 disease Diseases 0.000 description 2
- 230000004064 dysfunction Effects 0.000 description 2
- 210000002683 foot Anatomy 0.000 description 2
- 239000008187 granular material Substances 0.000 description 2
- 230000007813 immunodeficiency Effects 0.000 description 2
- 239000004615 ingredient Substances 0.000 description 2
- 208000014674 injury Diseases 0.000 description 2
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 description 2
- 208000028867 ischemia Diseases 0.000 description 2
- 230000003902 lesion Effects 0.000 description 2
- 201000006417 multiple sclerosis Diseases 0.000 description 2
- 201000001119 neuropathy Diseases 0.000 description 2
- 230000007823 neuropathy Effects 0.000 description 2
- 230000036407 pain Effects 0.000 description 2
- 230000037324 pain perception Effects 0.000 description 2
- 230000007170 pathology Effects 0.000 description 2
- 208000033808 peripheral neuropathy Diseases 0.000 description 2
- 230000008733 trauma Effects 0.000 description 2
- 206010044652 trigeminal neuralgia Diseases 0.000 description 2
- 239000003981 vehicle Substances 0.000 description 2
- 206010002091 Anaesthesia Diseases 0.000 description 1
- 108010011485 Aspartame Proteins 0.000 description 1
- COVZYZSDYWQREU-UHFFFAOYSA-N Busulfan Chemical compound CS(=O)(=O)OCCCCOS(C)(=O)=O COVZYZSDYWQREU-UHFFFAOYSA-N 0.000 description 1
- 208000020446 Cardiac disease Diseases 0.000 description 1
- 235000005979 Citrus limon Nutrition 0.000 description 1
- 244000131522 Citrus pyriformis Species 0.000 description 1
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 1
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
- 208000001640 Fibromyalgia Diseases 0.000 description 1
- 108010015776 Glucose oxidase Proteins 0.000 description 1
- 239000004366 Glucose oxidase Substances 0.000 description 1
- 102000004877 Insulin Human genes 0.000 description 1
- 108090001061 Insulin Proteins 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 1
- 229930195725 Mannitol Natural products 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- 240000008042 Zea mays Species 0.000 description 1
- 235000005824 Zea mays ssp. parviglumis Nutrition 0.000 description 1
- 235000002017 Zea mays subsp mays Nutrition 0.000 description 1
- 230000005856 abnormality Effects 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- 239000004480 active ingredient Substances 0.000 description 1
- 239000000443 aerosol Substances 0.000 description 1
- 239000003708 ampul Substances 0.000 description 1
- 230000037005 anaesthesia Effects 0.000 description 1
- 229940035676 analgesics Drugs 0.000 description 1
- 229940035674 anesthetics Drugs 0.000 description 1
- 239000000730 antalgic agent Substances 0.000 description 1
- 229940125681 anticonvulsant agent Drugs 0.000 description 1
- 239000001961 anticonvulsive agent Substances 0.000 description 1
- 239000000935 antidepressant agent Substances 0.000 description 1
- 229940005513 antidepressants Drugs 0.000 description 1
- 239000000605 aspartame Substances 0.000 description 1
- 235000010357 aspartame Nutrition 0.000 description 1
- IAOZJIPTCAWIRG-QWRGUYRKSA-N aspartame Chemical compound OC(=O)C[C@H](N)C(=O)N[C@H](C(=O)OC)CC1=CC=CC=C1 IAOZJIPTCAWIRG-QWRGUYRKSA-N 0.000 description 1
- 229960003438 aspartame Drugs 0.000 description 1
- SIKJAQJRHWYJAI-UHFFFAOYSA-N benzopyrrole Natural products C1=CC=C2NC=CC2=C1 SIKJAQJRHWYJAI-UHFFFAOYSA-N 0.000 description 1
- 230000033228 biological regulation Effects 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- 239000000872 buffer Substances 0.000 description 1
- XAAHAAMILDNBPS-UHFFFAOYSA-L calcium hydrogenphosphate dihydrate Chemical compound O.O.[Ca+2].OP([O-])([O-])=O XAAHAAMILDNBPS-UHFFFAOYSA-L 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 210000003169 central nervous system Anatomy 0.000 description 1
- 230000001684 chronic effect Effects 0.000 description 1
- 238000011260 co-administration Methods 0.000 description 1
- 239000003086 colorant Substances 0.000 description 1
- 235000005822 corn Nutrition 0.000 description 1
- 239000006071 cream Substances 0.000 description 1
- 230000003412 degenerative effect Effects 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 208000035475 disorder Diseases 0.000 description 1
- 230000000694 effects Effects 0.000 description 1
- 239000003995 emulsifying agent Substances 0.000 description 1
- 239000005454 flavour additive Substances 0.000 description 1
- 235000013355 food flavoring agent Nutrition 0.000 description 1
- 235000003599 food sweetener Nutrition 0.000 description 1
- 230000002496 gastric effect Effects 0.000 description 1
- 239000003193 general anesthetic agent Substances 0.000 description 1
- 229940116332 glucose oxidase Drugs 0.000 description 1
- 235000019420 glucose oxidase Nutrition 0.000 description 1
- 230000002641 glycemic effect Effects 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 208000019622 heart disease Diseases 0.000 description 1
- PZOUSPYUWWUPPK-UHFFFAOYSA-N indole Natural products CC1=CC=CC2=C1C=CN2 PZOUSPYUWWUPPK-UHFFFAOYSA-N 0.000 description 1
- -1 indole compound Chemical class 0.000 description 1
- RKJUIXBNRJVNHR-UHFFFAOYSA-N indolenine Natural products C1=CC=C2CC=NC2=C1 RKJUIXBNRJVNHR-UHFFFAOYSA-N 0.000 description 1
- 229940125396 insulin Drugs 0.000 description 1
- 238000007912 intraperitoneal administration Methods 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- 239000002502 liposome Substances 0.000 description 1
- 239000011777 magnesium Substances 0.000 description 1
- 229910052749 magnesium Inorganic materials 0.000 description 1
- 239000000845 maltitol Substances 0.000 description 1
- 235000010449 maltitol Nutrition 0.000 description 1
- VQHSOMBJVWLPSR-WUJBLJFYSA-N maltitol Chemical compound OC[C@H](O)[C@@H](O)[C@@H]([C@H](O)CO)O[C@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O VQHSOMBJVWLPSR-WUJBLJFYSA-N 0.000 description 1
- 229940035436 maltitol Drugs 0.000 description 1
- 239000000594 mannitol Substances 0.000 description 1
- 235000010355 mannitol Nutrition 0.000 description 1
- 210000005036 nerve Anatomy 0.000 description 1
- 210000000653 nervous system Anatomy 0.000 description 1
- 229940021182 non-steroidal anti-inflammatory drug Drugs 0.000 description 1
- 239000002674 ointment Substances 0.000 description 1
- 239000000014 opioid analgesic Substances 0.000 description 1
- 229940005483 opioid analgesics Drugs 0.000 description 1
- 238000000253 optical time-domain reflectometry Methods 0.000 description 1
- 230000003204 osmotic effect Effects 0.000 description 1
- 201000008482 osteoarthritis Diseases 0.000 description 1
- 239000006072 paste Substances 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 238000011552 rat model Methods 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 206010039073 rheumatoid arthritis Diseases 0.000 description 1
- 230000035945 sensitivity Effects 0.000 description 1
- 230000001953 sensory effect Effects 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 239000000600 sorbitol Substances 0.000 description 1
- 239000003381 stabilizer Substances 0.000 description 1
- 239000008107 starch Substances 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 239000008174 sterile solution Substances 0.000 description 1
- 230000001954 sterilising effect Effects 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- 239000000829 suppository Substances 0.000 description 1
- 239000004094 surface-active agent Substances 0.000 description 1
- 238000001356 surgical procedure Methods 0.000 description 1
- 238000013268 sustained release Methods 0.000 description 1
- 239000012730 sustained-release form Substances 0.000 description 1
- 239000003765 sweetening agent Substances 0.000 description 1
- 239000006188 syrup Substances 0.000 description 1
- 235000020357 syrup Nutrition 0.000 description 1
- 239000003826 tablet Substances 0.000 description 1
- MKTAGSRKQIGEBH-SSDOTTSWSA-N tebanicline Chemical compound C1=NC(Cl)=CC=C1OC[C@@H]1NCC1 MKTAGSRKQIGEBH-SSDOTTSWSA-N 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 230000000472 traumatic effect Effects 0.000 description 1
- 238000005303 weighing Methods 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5365—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines ortho- or peri-condensed with heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
Landscapes
- Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Epidemiology (AREA)
- Neurology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biomedical Technology (AREA)
- Pain & Pain Management (AREA)
- Neurosurgery (AREA)
- Rheumatology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Indole Compounds (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| IT001467A ITMI20031467A1 (it) | 2003-07-18 | 2003-07-18 | Farmaco attivo nel dolore neuropatico |
| PCT/EP2004/007633 WO2005014001A1 (en) | 2003-07-18 | 2004-07-08 | Use of 2h- [1, 3] - oxazino [3, 2-a] indole derivatives for the treatment of neuropathic pain |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| EA200600270A1 EA200600270A1 (ru) | 2006-06-30 |
| EA008927B1 true EA008927B1 (ru) | 2007-08-31 |
Family
ID=34131193
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| EA200600270A EA008927B1 (ru) | 2003-07-18 | 2004-07-08 | Применение производных 2h-[1,3]оксазино[3,2-a]индола для лечения невропатической боли |
Country Status (20)
| Country | Link |
|---|---|
| US (1) | US20060211691A1 (https=) |
| EP (1) | EP1646391B1 (https=) |
| JP (1) | JP2006528142A (https=) |
| KR (1) | KR20060033784A (https=) |
| CN (1) | CN100409850C (https=) |
| AR (1) | AR045993A1 (https=) |
| AT (1) | ATE345137T1 (https=) |
| AU (1) | AU2004262876B2 (https=) |
| CA (1) | CA2526852C (https=) |
| DE (1) | DE602004003252T2 (https=) |
| DK (1) | DK1646391T3 (https=) |
| EA (1) | EA008927B1 (https=) |
| ES (1) | ES2276317T3 (https=) |
| GE (1) | GEP20084307B (https=) |
| IL (1) | IL172156A0 (https=) |
| IT (1) | ITMI20031467A1 (https=) |
| PL (1) | PL1646391T3 (https=) |
| PT (1) | PT1646391E (https=) |
| UA (1) | UA81050C2 (https=) |
| WO (1) | WO2005014001A1 (https=) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP5023074B2 (ja) * | 2006-12-26 | 2012-09-12 | 大鵬薬品工業株式会社 | 糖尿病性ニューロパチー治療剤 |
| DE102007058504A1 (de) | 2007-12-05 | 2009-07-09 | Acino Ag | Transdermales therapeutisches System mit einem Gehalt an einem Modulator für nikotinische Acetylcholinrezeptoren (nAChR) |
| WO2025077825A1 (en) * | 2023-10-13 | 2025-04-17 | Fauna Bio Incorporated | Methods and compositions for treating cardio-pulmonary disorders |
Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO1993006108A1 (en) * | 1991-09-27 | 1993-04-01 | Fujisawa Pharmaceutical Co., Ltd. | Pyrrolobenzoxazine derivatives as 5-ht agonists and antagonists |
| US5817676A (en) * | 1995-03-16 | 1998-10-06 | Eli Lilly And Company | Indazolecarboxamides |
| EP0884319A2 (en) * | 1992-03-12 | 1998-12-16 | Smithkline Beecham Plc | [1,3]oxazino[3,2-A]indole derivative |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5189041A (en) * | 1990-11-16 | 1993-02-23 | Syntex (U.S.A.) Inc. | Tricyclic 5-ht3 receptor antagonists |
| NZ527771A (en) * | 1999-08-04 | 2005-04-29 | Icagen Inc | Methods for treating or preventing anxiety |
| US20040038874A1 (en) * | 2002-08-22 | 2004-02-26 | Osemwota Omoigui | Method of treatment of persistent pain |
-
2003
- 2003-07-18 IT IT001467A patent/ITMI20031467A1/it unknown
-
2004
- 2004-07-08 PL PL04740899T patent/PL1646391T3/pl unknown
- 2004-07-08 AU AU2004262876A patent/AU2004262876B2/en not_active Ceased
- 2004-07-08 GE GEAP20049233A patent/GEP20084307B/en unknown
- 2004-07-08 WO PCT/EP2004/007633 patent/WO2005014001A1/en not_active Ceased
- 2004-07-08 DE DE602004003252T patent/DE602004003252T2/de not_active Expired - Lifetime
- 2004-07-08 AT AT04740899T patent/ATE345137T1/de active
- 2004-07-08 EA EA200600270A patent/EA008927B1/ru not_active IP Right Cessation
- 2004-07-08 PT PT04740899T patent/PT1646391E/pt unknown
- 2004-07-08 EP EP04740899A patent/EP1646391B1/en not_active Expired - Lifetime
- 2004-07-08 ES ES04740899T patent/ES2276317T3/es not_active Expired - Lifetime
- 2004-07-08 DK DK04740899T patent/DK1646391T3/da active
- 2004-07-08 US US10/560,836 patent/US20060211691A1/en not_active Abandoned
- 2004-07-08 CN CNB2004800172642A patent/CN100409850C/zh not_active Expired - Fee Related
- 2004-07-08 KR KR1020067000490A patent/KR20060033784A/ko not_active Abandoned
- 2004-07-08 CA CA2526852A patent/CA2526852C/en not_active Expired - Fee Related
- 2004-07-08 JP JP2006520721A patent/JP2006528142A/ja active Pending
- 2004-07-15 AR ARP040102486A patent/AR045993A1/es not_active Application Discontinuation
- 2004-08-07 UA UAA200600306A patent/UA81050C2/uk unknown
-
2005
- 2005-11-24 IL IL172156A patent/IL172156A0/en not_active IP Right Cessation
Patent Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO1993006108A1 (en) * | 1991-09-27 | 1993-04-01 | Fujisawa Pharmaceutical Co., Ltd. | Pyrrolobenzoxazine derivatives as 5-ht agonists and antagonists |
| EP0884319A2 (en) * | 1992-03-12 | 1998-12-16 | Smithkline Beecham Plc | [1,3]oxazino[3,2-A]indole derivative |
| EP0630376B1 (en) * | 1992-03-12 | 1999-06-02 | Smithkline Beecham Plc | Condensed indole derivatives as 5-ht4-receptor antagonists |
| US5817676A (en) * | 1995-03-16 | 1998-10-06 | Eli Lilly And Company | Indazolecarboxamides |
Non-Patent Citations (5)
| Title |
|---|
| BEERS M. AND BERKOW R.: "The Merck Manual of Diagnosis and Therapy, Seventeenth Edition", 1999, MERCK RESEARCH LABORATORIES, WHITEHOUSE STATION, N.J., XP002279568, page 1371, column 2, paragraph 2 - page 1372, column 2, paragraph 2 * |
| DOAK G.J.; SAWYNOK J.: "Formalin-induced nociceptive behavior and edema: involvement of multiple peripheral 5-hydroxytryptamine receptor subtypes", NEUROSCIENCE, vol. 80, no. 3, 1997, pages 939-949, XP000886556, abstract page 939, column 2, paragraph 2 page 940, column 2, paragraph 3 page 944, column 1, paragraph 2 page 946, column 1, paragraph 2 page 946, column 2, paragraph 1 page 948, column 2, paragraph 1 * |
| DONAHUE ET AL.: "Electrolytic lesion of the anterior cingulate cortex decreases inflammatory, but not neuropathic nociceptive behavior in rats", BRAIN RESEARCH, vol. 897, no. 1-2, 2001, pages 131-138, XPO02279567, page 132, column 1, paragraph 2 * |
| HOUGHTON L.A. ET AL.: "5-HT4 receptor antagonism in irritable bowel syndrome: Effect of SB - 207266 -A on rectal sensitivity and small bowel transit". ALIMENTARY PHARMACOLOGY AND THERAPEUTICS, 13/11 (1437-1444). REFS: 32 ISSN: 0269-2813 CODEN: APTHEN, 1999, XP008037091, abstract page 1437, column 1, paragraph 1 - page 1438, column 1, paragraph 2 page 1441, column 2, paragraph 5 * |
| WEI H. ET AL.: "Influence of two serotonin receptor antagonists in neuropathic rats", PFLUEGERS ARCHIV EUROPEAN JOURNAL OF PHYSIOLOGY, vol. 443, no. Supplement 1, March 2002 (2002-03), page S181, XP001202624 & 81ST ANNUAL JOINT MEETING OF THE PHYSIOLOGICAL SOCIETY, THE SCANDINAVIAN PHYSIOLOGICAL SOCIETY AND T; TUEBINGEN, GERMANY; MARCH 15-19, 2002, ISSN: 0031-6768, the whole document * |
Also Published As
| Publication number | Publication date |
|---|---|
| GEP20084307B (en) | 2008-02-11 |
| EP1646391A1 (en) | 2006-04-19 |
| CN1809361A (zh) | 2006-07-26 |
| UA81050C2 (en) | 2007-11-26 |
| HK1087027A1 (en) | 2006-10-06 |
| AR045993A1 (es) | 2005-11-23 |
| JP2006528142A (ja) | 2006-12-14 |
| WO2005014001A1 (en) | 2005-02-17 |
| CA2526852A1 (en) | 2005-02-17 |
| CN100409850C (zh) | 2008-08-13 |
| DK1646391T3 (da) | 2007-03-19 |
| EA200600270A1 (ru) | 2006-06-30 |
| DE602004003252T2 (de) | 2007-05-03 |
| AU2004262876A1 (en) | 2005-02-17 |
| ATE345137T1 (de) | 2006-12-15 |
| WO2005014001A9 (en) | 2005-05-26 |
| ES2276317T3 (es) | 2007-06-16 |
| DE602004003252D1 (de) | 2006-12-28 |
| IL172156A0 (en) | 2006-04-10 |
| CA2526852C (en) | 2011-08-30 |
| AU2004262876B2 (en) | 2010-05-20 |
| ITMI20031467A1 (it) | 2005-01-19 |
| US20060211691A1 (en) | 2006-09-21 |
| EP1646391B1 (en) | 2006-11-15 |
| PT1646391E (pt) | 2007-01-31 |
| PL1646391T3 (pl) | 2007-04-30 |
| KR20060033784A (ko) | 2006-04-19 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| TW201028147A (en) | Dosage regimen of an S1P receptor agonist | |
| JP2004531468A5 (https=) | ||
| JPH0717501B2 (ja) | 高めた無痛覚を与える製薬製品 | |
| RU2006109467A (ru) | Способы лечения рака с использованием ингибиторов hdac | |
| RU2004136853A (ru) | (s)-4-амино-5-хлор-2-метокси-n-[1-[1-(2-тетрагидрофурилкарбонил)-4- пиперидини лметил]-4-пиперидинил]бензамид, способ его получения, содержащая его фармацевтическая композиция и промежуточное соединение для его получения | |
| JP2021008496A (ja) | インドール化合物を用いた疼痛又は間質性膀胱炎の治療方法 | |
| EA008927B1 (ru) | Применение производных 2h-[1,3]оксазино[3,2-a]индола для лечения невропатической боли | |
| EP2146713B1 (fr) | Utilisation du 4-cyclopropylmethoxy-n-(3,5-dichloro-1-oxydo-4- pyridin-4-yl)-5-(methoxy)pyridine-2-carboxamide pour le traitement des traumatismes craniens | |
| EP1646387B1 (en) | Use of indazole derivatives for the treatment of neuropathic pain | |
| JP2616845B2 (ja) | システノール酸又はその胆汁酸抱合体を含有する血中コレステロール低下剤 | |
| EP1611901B1 (en) | Preventive or remedy for teeth grinding | |
| JPH02288823A (ja) | 筋弛緩剤 | |
| RU2101011C1 (ru) | Средство, обладающее анальгетическим действием | |
| RU2289400C2 (ru) | Способ лечения острого иксодового клещевого боррелиоза на фоне хронического описторхоза | |
| JP5055474B2 (ja) | 治療上の使用のためのチアゾロピリミジン | |
| HK1087027B (en) | Use of 2h-[1, 3]-oxazino[3,2-a]indole derivatives for the treatment of neuropathic pain | |
| WO2021024855A1 (ja) | 線維筋痛症の治療薬又は予防薬 | |
| MXPA06000677A (es) | Uso de derivados de 2h-[1,3]-oxazino [3,2-a]indol para el tratamiento de dolor neuropatico | |
| HK1087026B (en) | Use of indazole derivatives for the treatment of neuropathic pain | |
| JPH0881366A (ja) | 多動性障害治療剤 | |
| HUP0402593A2 (hu) | Kariporidból és ramiprilből álló kombinációs készítmény és alkalmazása | |
| JP2006213611A (ja) | １‐アミノシクロプロパンカルボン酸等を主成分とする脳卒中又は脳卒中後遺症の予防用又は治療用薬剤 | |
| JPH0491065A (ja) | シクロプロピル桂皮酸アミド誘導体および筋弛緩剤 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| MM4A | Lapse of a eurasian patent due to non-payment of renewal fees within the time limit in the following designated state(s) |
Designated state(s): AM AZ BY KZ KG MD TJ TM RU |